It has been demonstrated that combining ASCL1 with markers such as OTP, HNF1A or CD44 improves NETs subclassification, with identifying groups linked to clinical characteristics, including patient sex and tumor location [2, 7]. This evidence concerns the gene OTP and neoplasm.